Testing a new medication for blood cancers that haven't responded to other treatments

This is an early-stage research study testing a new medication called rebecsinib for people with certain blood cancers — specifically secondary acute myeloid leukemia or high-risk myelofibrosis — that have stopped responding to standard treatments. Researchers want to find the safest and most effective dose of this medication, understand how it works in your body, and see how well it helps control the disease. The medication is given through injections on specific days over a 4-week cycle.

Many patients with these aggressive blood cancers have limited options after standard chemotherapy and other treatments stop working. This medication works through a different mechanism than existing treatments, potentially offering hope to patients who have run out of other choices.